AUB ScholarWorks

Successful retreatment with infliximab in patients with prior severe infusion reactions

Show simple item record

dc.contributor.author Uthman I.
dc.contributor.author Touma Z.
dc.contributor.author El-Sayyad J.
dc.contributor.author Zaitoun F.
dc.contributor.editor
dc.date Jul-2006
dc.date.accessioned 2017-10-05T15:40:38Z
dc.date.available 2017-10-05T15:40:38Z
dc.date.issued 2006
dc.identifier 10.1007/s10067-005-0029-9
dc.identifier.isbn
dc.identifier.issn 07703198
dc.identifier.uri http://hdl.handle.net/10938/17552
dc.description.abstract Infusion of the antitumor necrosis factor-α chimeric monoclonal antibody infliximab can be associated with the development of severe infusion reactions (IR) during retreatment. We present the case of two rheumatoid arthritis patients with a history of severe acute IR to infliximab who subsequently underwent successful infusion using a prophylactic treatment with a combination of H1 and H2 receptor blockers, hydrocortisone, and diphenhydramine. © Clinical Rheumatology 2005.
dc.format.extent
dc.format.extent Pages: (540-541)
dc.language English
dc.publisher NEW YORK
dc.relation.ispartof Publication Name: Clinical Rheumatology; Publication Year: 2006; Volume: 25; no. 4; Pages: (540-541);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Successful retreatment with infliximab in patients with prior severe infusion reactions
dc.type Article
dc.contributor.affiliation Uthman, I., Division of Rheumatology, Faculty of Medicine, American University of Beirut, 113-6044 Beirut, Lebanon
dc.contributor.affiliation Touma, Z., Division of Rheumatology, Faculty of Medicine, American University of Beirut, 113-6044 Beirut, Lebanon
dc.contributor.affiliation El-Sayyad, J., Division of Rheumatology, Faculty of Medicine, American University of Beirut, 113-6044 Beirut, Lebanon
dc.contributor.affiliation Zaitoun, F., Division of Rheumatology, Faculty of Medicine, American University of Beirut, 113-6044 Beirut, Lebanon
dc.contributor.authorAddress Uthman, I.; Division of Rheumatology, Faculty of Medicine, American University of Beirut, 113-6044 Beirut, Lebanon; email: iuthman@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Rheumatology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Rheumatology
dc.contributor.authorEmail iuthman@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Uthman, I
dc.contributor.authorInitials Touma, Z
dc.contributor.authorInitials El-Sayyad, J
dc.contributor.authorInitials Zaitoun, F
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Uthman, I (reprint author), Amer Univ Beirut, Med Ctr, Fac Med, Div Rheumatol, Beirut 1136044, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016-S0002-9270(03)00231-4; Colombel JF, 2004, GASTROENTEROLOGY, V126, P19, DOI 10.1053-j.gastro.2003.10.047; Cush JJ, 2004, RHEUM DIS CLIN N AM, V30, P237, DOI 10.1016-j.rdc.2004.02.003; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016-S0140-6736(02)08512-4; Kugathasan S, 2002, AM J GASTROENTEROL, V97, P1408, DOI 10.1016-S0002-9270(02)04140-0; Lin RY, 2000, ANN EMERG MED, V36, P462, DOI 10.1067-mem.2000.109445; Marone Gianni, 2003, Journal of Allergy and Clinical Immunology, V112, pS83, DOI 10.1016-S0091-6749(03)01881-5; Schaible TF, 2000, CAN J GASTROENTER SC, V14, P29; Wasserman MJ, 2004, J RHEUMATOL, V31, P1912
dc.description.citedCount 7
dc.description.citedTotWOSCount 6
dc.description.citedWOSCount 6
dc.format.extentCount 2
dc.identifier.articleNo
dc.identifier.coden CLRHD
dc.identifier.pubmedID 16211336
dc.identifier.scopusID 33746528626
dc.identifier.url
dc.publisher.address 233 SPRING STREET, NEW YORK, NY 10013 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Clin. Rheumatol.
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Clinical Rheumatology
dc.relation.ispartofPubTitleAbbr Clin. Rheumatol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 25
dc.source.ID WOS:000238817400023
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS diphenhydramine, 147-24-0, 58-73-1
dc.subject.otherChemCAS fexofenadine, 138452-21-8
dc.subject.otherChemCAS hydrocortisone, 50-23-7
dc.subject.otherChemCAS infliximab, 170277-31-3
dc.subject.otherChemCAS leflunomide, 75706-12-6
dc.subject.otherChemCAS methotrexate, 15475-56-6, 59-05-2, 7413-34-5
dc.subject.otherChemCAS paracetamol, 103-90-2
dc.subject.otherChemCAS prednisone, 53-03-2
dc.subject.otherChemCAS ranitidine, 66357-35-5, 66357-59-3
dc.subject.otherChemCAS Antibodies, Monoclonal
dc.subject.otherChemCAS Diphenhydramine, 58-73-1
dc.subject.otherChemCAS Histamine H1 Antagonists
dc.subject.otherChemCAS Histamine H2 Antagonists
dc.subject.otherChemCAS Hydrocortisone, 50-23-7
dc.subject.otherChemCAS infliximab
dc.subject.otherIndex diphenhydramine
dc.subject.otherIndex fexofenadine
dc.subject.otherIndex histamine H1 receptor antagonist
dc.subject.otherIndex histamine H2 receptor antagonist
dc.subject.otherIndex hydrocortisone
dc.subject.otherIndex infliximab
dc.subject.otherIndex leflunomide
dc.subject.otherIndex methotrexate
dc.subject.otherIndex paracetamol
dc.subject.otherIndex prednisone
dc.subject.otherIndex ranitidine
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex anaphylaxis
dc.subject.otherIndex article
dc.subject.otherIndex case report
dc.subject.otherIndex clinical feature
dc.subject.otherIndex clinical protocol
dc.subject.otherIndex disease severity
dc.subject.otherIndex drug hypersensitivity
dc.subject.otherIndex drug infusion
dc.subject.otherIndex drug reexposure
dc.subject.otherIndex drug surveillance program
dc.subject.otherIndex drug tolerability
dc.subject.otherIndex drug withdrawal
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex monotherapy
dc.subject.otherIndex priority journal
dc.subject.otherIndex rheumatoid arthritis
dc.subject.otherIndex risk benefit analysis
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex Antibodies, Monoclonal
dc.subject.otherIndex Arthritis, Rheumatoid
dc.subject.otherIndex Diphenhydramine
dc.subject.otherIndex Drug Administration Schedule
dc.subject.otherIndex Drug Therapy, Combination
dc.subject.otherIndex Female
dc.subject.otherIndex Histamine H1 Antagonists
dc.subject.otherIndex Histamine H2 Antagonists
dc.subject.otherIndex Humans
dc.subject.otherIndex Hydrocortisone
dc.subject.otherIndex Infusions, Intravenous
dc.subject.otherIndex Retreatment
dc.subject.otherIndex Treatment Outcome
dc.subject.otherKeywordPlus CROHNS-DISEASE
dc.subject.otherKeywordPlus EXPERIENCE
dc.subject.otherWOS Rheumatology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account